Imprimis Pharmaceuticals Stock News

AKZOY, GTX and HROW have been added to the Zacks Rank #5 (Strong Sell) List on November 14, 2023.

Harrow, Inc. (NASDAQ:HROW ) Q3 2023 Earnings Conference Call November 13, 2023 4:45 PM ET Corporate Participants Jamie Webb - Director-Communications & Investor Relations Mark Baum - Chief Executive O

Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong customer relationships make it possible for them to acq

Harrow Health, Inc. (NASDAQ:HROW ) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Execut

Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interestin

Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road

Harrow added seven new products through an acquisition. The company said it expects increased revenue year over year in the second quarter.

Harrow Health (HROW) closed at $18.52 in the latest trading session, marking no change from the prior day.

Harrow Healthcare is well-positioned to grow in the US Ophthalmology market, with a branded pharma sales strategy that could boost growth and margins. The company's medium-term earnings outlook is str

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like MicroStrategy (MSTR), SPX Technologies (SPXC), Cvent (CVT), Harrow Health (HROW) and Banco (BM

Harrow had a $6.6 million loss in the first quarter. It just launched its latest therapy, the ocular anesthesia Iheeza.

Harrow Health, Inc. (NASDAQ:HROW ) Q1 2023 Earnings Conference Call May 11, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew

Harrow Health (HROW) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.03 per share a year ago.

Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.